CERE DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - CERE

Core Viewpoint - Rosen Law Firm is reminding investors who sold or held shares of Cerevel Therapeutics Holdings, Inc. during a specified period about their potential entitlement to compensation through a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from October 11, 2023, to August 1, 2024, and includes those who held shares as of January 8, 2024, and those who sold shares around Bain Capital's purchase on October 16, 2023 [1]. - Investors may join the class action without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must be appointed by June 3, 2025, to represent other class members in the litigation [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [4]. - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019 and has been consistently ranked among the top firms in securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that during the class period, Cerevel's controlling shareholders made false statements related to a secondary stock offering on October 16, 2023, which allowed Bain Capital to acquire shares at a discounted price before AbbVie Inc.'s acquisition announcement [5]. - Following the acquisition announcement, Cerevel's stock was valued at$45 per share, nearly double the offering price, resulting in Bain Capital receiving over $120 million in windfall profits [5].